The Depo-Provera lawsuit update for 2026 is significant: thousands of women across the United States are now part of a growing mass tort claiming the birth control shot caused brain tumors. This litigation is one of the fastest-growing pharmaceutical injury cases in the country right now.
The core allegation is direct. Women who used Depo-Provera, a injectable contraceptive made with medroxyprogesterone acetate, developed intracranial meningiomas at alarming rates. Plaintiffs say Pfizer knew the risk and failed to warn them.
In this article, you’ll get the full picture. That means the science, the legal status, who qualifies, what settlement figures look like, and exactly what’s happening inside the courtroom in 2026.
One fact that sets this case apart: a landmark French study published in 2024 found that women who used high-dose progestogens like Depo-Provera were up to 5.6 times more likely to develop intracranial meningiomas than non-users.
Depo-Provera Lawsuit Update 2026: Where Things Stand Right Now
The Depo-Provera lawsuit is active and accelerating in 2026, with MDL No. 3140 now consolidated in the Northern District of Illinois. The case docket has grown to include thousands of individual plaintiffs.
Judges overseeing the MDL have set aggressive scheduling orders. Discovery is ongoing. Bellwether trial selections are expected to move forward in the first half of 2026, which is a major step toward potential settlement negotiations.
What this means for you is simple. If you used Depo-Provera and developed a brain tumor, the window to file is open but not infinite. Statutes of limitations vary by state, and courts have been tracking filing deadlines carefully.
| Status Item | Current Status (2026) |
|---|---|
| MDL Case Number | MDL No. 3140 |
| Court | Northern District of Illinois |
| MDL Judge | Assigned federal district judge |
| Total Cases Filed | Thousands and growing |
| Discovery Phase | Active |
| Bellwether Trials | Selection phase underway |
| Settlement Talks | Pre-trial, not yet announced |
The litigation is not slowing down. If anything, new plaintiffs are joining the MDL at an increasing rate as awareness grows.
What Is the Depo-Provera Lawsuit About?
The Depo-Provera lawsuit is about one central claim: that Pfizer sold a birth control injection linked to brain tumors without adequately warning patients or doctors about the risk. Plaintiffs argue this is a textbook failure-to-warn case under product liability law.
Depo-Provera contains medroxyprogesterone acetate, a synthetic form of progesterone. Women receive injections every three months as a form of contraceptive. Millions of women in the U.S. have used it since its FDA approval.
The lawsuits allege that Pfizer had access to research suggesting elevated meningioma risk. Despite that, no clear warning appeared on labeling. Women made reproductive health decisions without knowing this risk.
The two main legal theories in these cases:
- Failure to warn: Pfizer did not disclose known risks on its product label.
- Negligence and product liability: The product was defectively designed or marketed without adequate safety disclosures.
The Depo-Provera Brain Tumor Lawsuit Explained
The Depo-Provera brain tumor lawsuit centers on meningiomas, which are tumors that grow on the membranes surrounding the brain and spinal cord. Most meningiomas are not cancerous in the traditional sense, but they can still cause serious, life-altering harm.
These tumors press against brain tissue. Depending on location, they can cause vision loss, hearing problems, cognitive decline, seizures, and severe headaches. Surgery to remove them carries its own significant risks.
Women in the lawsuit say they underwent brain surgeries, radiation, and in some cases multiple procedures after developing these tumors. Many were left with permanent neurological damage.
Common symptoms alleged by plaintiffs:
- Persistent headaches that worsened over time
- Visual disturbances or sudden vision changes
- Hearing loss or ringing in the ears
- Memory problems and cognitive decline
- Seizures
- Weakness on one side of the body
The connection to Depo-Provera is not speculative. The scientific evidence underpinning these claims is growing stronger, and courts have so far allowed the cases to proceed.
Key Takeaway: The Depo-Provera brain tumor lawsuit involves serious injuries including meningiomas requiring surgery, and MDL No. 3140 is currently active and advancing in federal court.
Depo-Provera Meningioma Risk and Side Effects
Depo-Provera’s connection to meningioma comes from the drug’s active ingredient, medroxyprogesterone acetate (MPA), a synthetic progestogen with strong hormonal activity. Meningioma tumors carry progesterone receptors, meaning they can respond to hormonal signals.
High-dose or long-term MPA exposure is now widely theorized to accelerate meningioma growth. Women who used Depo-Provera for longer periods or at higher cumulative doses appear to face the greatest risk.
Other side effects of Depo-Provera that have been documented over the years include bone density loss, irregular bleeding, and mood changes. But the meningioma link is what drives the current litigation.
| Side Effect | Severity | Linked to Litigation |
|---|---|---|
| Intracranial meningioma | Severe | Yes, primary claim |
| Bone density reduction | Moderate | Historical concern |
| Irregular menstrual bleeding | Moderate | No |
| Mood changes/depression | Moderate | No |
| Weight changes | Mild | No |
The meningioma risk is dose-dependent according to current research. Women who received injections over several years carry a higher risk profile than those who used the drug briefly.
Pfizer’s Role in the Depo-Provera Lawsuit
Pfizer is the primary defendant in the Depo-Provera lawsuit, and the company’s history with this product is a central part of the case. Pfizer acquired Pharmacia in 2003, and with that acquisition came ownership of the Depo-Provera brand.
Plaintiffs argue that Pfizer had access to safety data and scientific literature that should have prompted updated warnings long before lawsuits began piling up. The argument is that a company with Pfizer’s resources had both the knowledge and the means to investigate and disclose the meningioma risk.
Pfizer has denied wrongdoing and contested the scientific claims. That’s standard posture for a defendant in early-stage litigation. But the number of cases filing against Pfizer has not slowed, and the MDL’s continuation signals that courts see enough merit to proceed.
Think of it like a car company that gets early crash-test data showing a rollover risk. The question in court is: when did they know, and what did they do with that information?
Pfizer’s known defenses so far:
- Scientific causation is disputed
- Product labeling met regulatory standards at the time
- Plaintiffs cannot prove individual causation
Who Qualifies for the Depo-Provera Lawsuit?
You may qualify for the Depo-Provera lawsuit if you used Depo-Provera injections and were later diagnosed with an intracranial meningioma. These are the core eligibility requirements that most plaintiffs’ attorneys are applying.
The diagnosis must be documented by imaging, usually an MRI or CT scan, and confirmed by a physician. A brain tumor diagnosis without proper medical documentation is not sufficient to join the litigation.
Timing also matters. Most attorneys are looking at cases where Depo-Provera use occurred over a sustained period, typically one year or longer, though shorter-term users with documented meningiomas are being evaluated on a case-by-case basis.
| Eligibility Factor | Requirement |
|---|---|
| Product Used | Depo-Provera (medroxyprogesterone acetate injection) |
| Injury Required | Intracranial meningioma diagnosis |
| Documentation | Medical records, MRI/CT scan, physician diagnosis |
| Duration of Use | Generally 1 year or more (shorter cases reviewed individually) |
| Timeframe | Use must predate meningioma diagnosis |
| State Deadlines | Varies by state statute of limitations |
Family members of women who died from meningioma after Depo-Provera use may also have a wrongful death claim. These claims follow the same general eligibility criteria.
Key Takeaway: To qualify for the Depo-Provera lawsuit, you generally need documented Depo-Provera use, an intracranial meningioma diagnosis, and medical records supporting both, with eligibility varying based on state filing deadlines.
The Science Behind Depo-Provera Intracranial Meningioma Claims
The scientific case against Depo-Provera is stronger than most people realize, and it got significantly stronger in 2024. The PRESAGE study, a French epidemiological cohort study published in the British Medical Journal in 2024, analyzed over 18,000 women with intracranial meningioma.
Its findings were striking. Women who used high-dose progestogens, including MPA (the active ingredient in Depo-Provera), faced a 5.6-fold increased risk of intracranial meningioma compared to non-users. That’s not a marginal statistical blip. That’s a substantial signal.
The study was observational, meaning it identified a strong association rather than proving direct causation in a clinical trial setting. But in mass tort litigation, epidemiological evidence like this has historically been powerful enough to support jury verdicts.
Key findings from the PRESAGE study:
- Over 18,000 meningioma cases analyzed
- 5.6x increased risk for high-dose progestogen users
- MPA specifically identified as a high-risk compound
- Risk increased with duration of use
- Published in a peer-reviewed medical journal in 2024
This study is expected to be central to expert testimony in the bellwether trials. Plaintiffs’ attorneys will use it to establish general causation, a key threshold in pharmaceutical mass tort cases.
Depo-Provera MDL Update 2026
MDL No. 3140 is the formal legal home of the Depo-Provera brain tumor litigation, and it’s housed in the U.S. District Court for the Northern District of Illinois. Multidistrict litigation consolidates thousands of related federal cases before a single judge for pretrial proceedings.
As of 2026, the MDL is in active pretrial discovery. That means both sides are exchanging documents, taking depositions, and building their scientific expert cases. This phase is expensive and intensive, and it typically runs for one to two years before trials begin.
The judge overseeing MDL No. 3140 has issued case management orders setting timelines for discovery completion and expert witness designations. These orders are binding on all plaintiffs in the MDL.
| MDL Phase | Description | Status |
|---|---|---|
| Consolidation | All federal cases moved to one court | Complete |
| Initial Case Management | Scheduling orders issued | Complete |
| Discovery | Document exchange, depositions | Active in 2026 |
| Expert Witness Designation | Scientific experts identified | Underway |
| Bellwether Selection | Test cases chosen for trial | Selection phase |
| Bellwether Trials | First trials heard | Expected 2026 to 2027 |
| Global Settlement Talks | Negotiations for mass resolution | Post-bellwether |
State court cases proceed separately from the MDL. Women who filed in state courts are not automatically part of MDL No. 3140.
What Are Depo-Provera Bellwether Trials?
Bellwether trials are test cases selected from the larger MDL to go to trial first, and they serve as a preview of how juries respond to the evidence. The term “bellwether” comes from the lead sheep in a flock. These first cases show which direction the herd will go.
In the Depo-Provera MDL, bellwether cases will be chosen to represent a cross-section of plaintiffs. Some may involve longer Depo-Provera use. Others may feature more severe injuries. The selection is designed to give both sides a realistic read on case value.
If plaintiffs win bellwether trials, Pfizer faces enormous pressure to settle the remaining thousands of cases. If defense wins, settlement values go down. Bellwether verdicts don’t bind other plaintiffs legally, but they shape negotiations powerfully.
Why bellwether trials matter to individual claimants:
- Verdicts set the informal price range for settlement
- They reveal what evidence resonates with juries
- They accelerate settlement talks for the full MDL
- They show weaknesses in both sides’ arguments
- They typically happen before a global settlement fund is created
Bellwether selection in the Depo-Provera MDL is expected to conclude in 2026, with the first trials potentially beginning in late 2026 or early 2027.
Key Takeaway: Bellwether trials are the critical next step in the Depo-Provera MDL, and their outcomes will directly determine how much compensation individual plaintiffs ultimately receive.
How to File a Depo-Provera Lawsuit Claim
Filing a Depo-Provera lawsuit claim starts with gathering your medical records and prescription history, not with calling a law firm first. Having documentation ready makes the intake process significantly faster.
You’ll want to collect records showing Depo-Provera injections were administered, records of your meningioma diagnosis, any imaging studies like MRIs or CT scans, and surgical or treatment records if applicable.
Once you have your records, you’ll work with a mass tort attorney to evaluate your claim. Most attorneys handling Depo-Provera cases work on a contingency basis, meaning they only get paid if you win. There are no upfront legal fees.
Steps to file a Depo-Provera claim:
- Gather medical records documenting Depo-Provera injections
- Obtain radiology reports confirming meningioma diagnosis
- Collect surgical, treatment, and hospital records
- Contact a mass tort attorney for a free case evaluation
- Sign a retainer agreement if your case qualifies
- Your attorney files your complaint in the appropriate court
- Your case is either filed directly into MDL No. 3140 or a parallel state proceeding
Important: Filing deadlines vary by state. Some states have statutes of limitations as short as two years from the date of diagnosis or from when you should have reasonably known about the Depo-Provera connection. Do not wait.
Depo-Provera Lawsuit Settlement Amount: What to Expect
No official Depo-Provera settlement has been announced as of 2026, because the case is still in pretrial phases. But based on comparable pharmaceutical mass tort settlements, analysts and legal observers have begun forming early estimates.
Mass tort settlements are not one-size-fits-all. They are tiered based on injury severity, duration of product use, extent of medical treatment required, and the degree of long-term harm.
In pharmaceutical brain injury cases of similar scale, individual settlements have historically ranged from $100,000 to over $1,000,000 for the most severe cases. Cases involving surgery, permanent neurological damage, or death tend to command the highest values.
| Injury Tier | Description | Estimated Range |
|---|---|---|
| Tier 1 (Severe) | Surgery, permanent neurological damage, disability | $500,000 to $1,000,000+ |
| Tier 2 (Moderate) | Diagnosis requiring treatment, significant impact | $200,000 to $500,000 |
| Tier 3 (Mild-Moderate) | Diagnosis with limited treatment or monitoring only | $100,000 to $200,000 |
| Wrongful Death | Family member died from meningioma | Case-dependent, often higher |
These figures are not guarantees. They reflect comparable case history and early analyst modeling. Actual settlements depend on bellwether outcomes, Pfizer’s litigation posture, and the overall number of valid claims filed.
Depo-Provera Lawsuit Payout 2026: Estimated Compensation Ranges
In 2026, no settlement payout has been distributed yet in the Depo-Provera litigation. Distributions don’t happen until after a settlement agreement is reached and a claims process is established.
Based on the litigation trajectory, legal analysts don’t expect a global settlement before 2027 at the earliest, assuming bellwether trials proceed on schedule. Once a settlement fund is created, individual payouts flow through a claims administrator.
Factors that determine your specific payout within a settlement tier include years of Depo-Provera use, the size and location of the meningioma, whether surgery was required, and documented impact on your quality of life.
Factors that increase your potential payout:
- Longer duration of Depo-Provera injections
- Multiple surgeries or recurrence of meningioma
- Permanent cognitive or neurological deficits
- Loss of employment or income due to injury
- Younger age at diagnosis
- Strong documentation and expert medical support
Getting a strong attorney with pharmaceutical mass tort experience is arguably the most direct way to improve your payout outcome. Case preparation quality matters significantly in tiered settlement systems.
Depo-Provera Class Action vs. Mass Tort: What’s the Difference?
The Depo-Provera lawsuit is a mass tort, not a class action, and that distinction matters for your potential compensation. Many people use these terms interchangeably, but they are fundamentally different legal structures.
In a class action, all plaintiffs receive the same settlement amount split across the group. One verdict covers everyone, and individual circumstances matter very little. Think of the old Facebook privacy settlement where users got a few dollars each.
In a mass tort, each plaintiff has an individual case with individual facts. Your compensation is determined by your specific injury, your specific medical history, and your specific documented harm. The Depo-Provera MDL preserves these individual cases while organizing them together for efficiency.
| Feature | Class Action | Mass Tort (MDL) |
|---|---|---|
| Individual Payout | Equal share of total fund | Based on individual injury |
| Case Structure | One case for everyone | Individual cases coordinated |
| Injury Evaluation | Not individualized | Fully individualized |
| Compensation Range | Usually small ($5 to $500) | Can be very large ($100K+) |
| Examples | Data breach, consumer fraud | Drug injury, medical device |
| Depo-Provera fits | No | Yes |
Mass tort litigation takes longer than class actions, but the potential payouts are substantially higher for individuals with serious injuries.
Key Takeaway: The Depo-Provera case is a mass tort, not a class action, meaning each plaintiff gets compensation based on their individual injury rather than a shared pool divided equally.
Depo-Provera Lawsuit Timeline: Key Dates and Phases
Understanding the timeline helps you manage expectations. Pharmaceutical mass torts don’t resolve in months. They typically span three to seven years from first filing to final distribution.
| Date / Period | Event |
|---|---|
| Pre-2024 | Isolated lawsuits filed, no MDL |
| Early 2024 | PRESAGE study published, litigation accelerates |
| Mid-2024 | MDL petition filed and granted |
| Late 2024 | MDL No. 3140 established in Northern District of Illinois |
| 2025 | Initial case management orders, discovery begins |
| 2026 | Active discovery, bellwether trial selection |
| Late 2026 to 2027 | First bellwether trials expected |
| 2027 to 2028 | Post-bellwether settlement negotiations |
| 2028 and beyond | Global settlement fund and distribution (estimated) |
These dates are projections based on typical MDL timelines. Court scheduling can move faster or slower depending on judicial priorities, case complexity, and settlement negotiations.
The PRESAGE study in 2024 was the single biggest catalyst for this litigation. Before that study, cases existed but the scientific foundation was thinner. After it, filing rates accelerated dramatically.
Depo-Provera Lawsuit News 2026: The Latest Developments
The biggest development in 2026 is the MDL’s transition from initial setup to active litigation. Courts are now deep in the discovery phase, and both sides are fighting over documents, internal communications, and scientific data.
Pfizer is expected to produce internal safety documents during discovery. In similar pharmaceutical cases, internal communications have proven to be some of the most damaging evidence for drug manufacturers. Plaintiffs’ attorneys are focused heavily on this document review.
Expert witness battles are another headline story in 2026. Both sides will bring in scientific experts to argue about general causation, the dose-response relationship between MPA and meningioma, and the reliability of the PRESAGE study. These battles often shape bellwether trial outcomes before a single juror is seated.
Key 2026 developments to watch:
- Completion of general causation expert briefing
- Court rulings on expert witness admissibility (Daubert hearings)
- Bellwether case selection finalized
- Potential bellwether trial dates set
- Additional studies on MPA and meningioma published
- Possible early individual settlements in select cases
State court cases in California, New York, and Illinois are also proceeding in parallel. Some state-level plaintiffs may see resolution before the federal MDL reaches a global settlement.
Is the Depo-Provera Lawsuit Still Active?
Yes, the Depo-Provera lawsuit is fully active in 2026, and new cases are still being accepted by plaintiffs’ attorneys. MDL No. 3140 is proceeding through the federal court system with no signs of slowing.
The litigation has not settled. No global settlement fund has been created. Individual plaintiffs who have not yet filed but meet the eligibility criteria should be aware that statutes of limitations are running. In most states, you have a limited window from the date of diagnosis or from the date you connected your injury to Depo-Provera.
For anyone wondering whether it’s too late, the honest answer is: it depends on your state and your specific situation. Most attorneys in this space offer free initial consultations and can tell you within minutes whether your claim is still viable.
| Question | Answer |
|---|---|
| Is MDL No. 3140 active? | Yes |
| Are new cases being accepted? | Yes |
| Has a settlement been reached? | No |
| Have bellwether trials happened? | Not yet as of early 2026 |
| Is there a filing deadline? | Yes, varies by state |
| Can I still join the lawsuit? | Likely yes, confirm with an attorney |
The Depo-Provera lawsuit is very much alive. The question is not whether this litigation is happening. The question is whether you act while the window is open.
Frequently Asked Questions
How much money can I get from the Depo-Provera lawsuit?
Estimated payouts range from $100,000 to over $1,000,000 depending on injury severity, duration of use, and documentation.
No settlement has been finalized yet, so these figures reflect projections based on comparable pharmaceutical mass tort cases.
Actual amounts will be determined after bellwether trials and settlement negotiations, likely beginning in 2027.
What brain tumor qualifies for the Depo-Provera lawsuit?
An intracranial meningioma is the tumor type at the center of this litigation.
Meningiomas grow on the membranes surrounding the brain and spinal cord and must be confirmed by MRI or CT scan.
Other brain tumor types are not currently the primary focus of these lawsuits, though cases may be evaluated individually.
How long does the Depo-Provera lawsuit take to settle?
Based on MDL timelines, a global settlement is not expected before 2027 to 2028 at the earliest.
Bellwether trials must happen first, and those are projected for late 2026 into 2027.
Individual cases may settle earlier if Pfizer negotiates select resolutions before a global deal.
Can I still file a Depo-Provera lawsuit in 2026?
Yes, new cases are still being filed and accepted in 2026.
Your ability to file depends on your state’s statute of limitations, which typically runs two to four years from the date of diagnosis or discovery of the Depo-Provera connection.
Act promptly. Statutes of limitations are hard deadlines, and courts will not grant extensions simply because a settlement has not yet been reached.
Did Pfizer know Depo-Provera caused brain tumors?
Plaintiffs allege that Pfizer had access to scientific data suggesting elevated meningioma risk and failed to update product warnings accordingly.
Pfizer disputes this and maintains its labeling met regulatory requirements at the time.
This question of corporate knowledge is expected to be central to bellwether trials and expert witness testimony.
What to Do Right Now
The Depo-Provera lawsuit in 2026 is at a critical turning point. Discovery is active. Bellwether trials are approaching. The litigation is real, it’s large, and it’s moving forward.
If you used Depo-Provera and were diagnosed with an intracranial meningioma, your priority should be gathering your medical records now. Time limits are real in this case.
Find a mass tort attorney with pharmaceutical experience and get a free case evaluation. You have nothing to lose by finding out whether your claim qualifies while the window is still open.
